Kao Corp.

Cha Bio Group, Kakao deepen partnership Cha Bio Group, one of South Korea's largest biotechnology and healthcare companies, will acquire a minority stake in Kakao Healthcare as part of a share-swap agreement with its parent firm, Kakao Corp. Through its subsidiaries Chacares and ChaAI Healthcare, the group will purchase 80 billion won worth of Kakao Healthcare shares—equivalent to about 43%—while CHA Biotech will raise 30 billion won in new capital allocated to Kakao. Kakao Healthcare also plans to secure 50 billion won from external investors by the first quarter of next year. The share swap will fold its mobile chronic disease platform, medical data platform, research portal, and hospital concierge service into Cha Bio Group’s global healthcare network. Taiwanese tech consortium targets Japan's elderly sector A private operator of elderly care facilities in Japan is looking to tap into integrated technology solutions by a consortium of manufacturers, software developers, and service providers in Taiwan. The 10-member Taiwan CareTech Alliance, led by Netown Corporation, a smart assistive device startup, signed a memorandum of understanding with Citrus Co. amid its expansion across the Japanese elderly care sector. It has also received interest from local distributors and orders totalling over $890,000, the consortium's press statement said. Qure.ai joins Microsoft's Precision Imaging Network Microsoft is onboarding Qure.ai's AI-powered lung cancer detection and management suite onto its marketplace platform for medical imaging AI. In a statement, the Indian company said its solutions will be onboarded onto Microsoft's Precision Imaging Network, which provides healthcare providers with access to a catalogue of third-party and regulated AI models. Approved by the United States Food and Drug Administration, Qure.ai's lung cancer solutions are powered by large language models and agentic AI to detect, measure, and quantify lung nodules on chest X-rays and CT scans, as well as manage workflows.

东方网记者程琦11月1日报道：随着第八届中国国际进口博览会（CIIE）的大幕即将于11月5日拉开，全球参展商的筹备工作已进入最后的冲刺阶段。在这座象征着开放与合作的“四叶草”场馆内，众多连续多年参展的跨国企业“老朋友”正蓄势待发，准备揭晓其为中国市场带来的最新创新成果。从全球首发的重磅新药，到深度融合本土场景的前沿科技，再到为中国消费者量身定制的日用精品，一场精彩纷呈的全球创新盛宴即将到来。 聚焦心血管领域，两大重磅新药上演“全球首秀” 作为进博会的“八年全勤生”，全球生物制药公司赛诺菲今年将以“追寻奇迹，筑梦为你”为主题，再次彰显其对中国市场的长期承诺。本届展会，赛诺菲将把医疗创新的焦点对准心血管疾病这一重大公共卫生挑战，并带来两款潜在“同类最佳”或“同类首创”药物的全球首次亮相，充分体现了其将最前沿研发成果第一时间惠及中国患者的决心。 届时，阿夫凯泰片将作为第二代心肌肌球蛋白抑制剂全球首秀，它精准靶向可导致青少年和运动员猝死的“隐藏杀手”——肥厚型心肌病（HCM）的病因，有望为患者开启靶向治疗的“精准调节”新时代。另一款全球首秀的普乐司兰钠注射液是一款创新的siRNA类药物，临床数据显示其能显著降低急性胰腺炎的发生风险，有望打破罕见病“家族性乳糜微粒血症综合征”当前“无药可控”的治疗困局，为患者带来全新希望。 创纪录首秀阵容，从药品到生产的全方位承诺 同样连续八年赴约的罗氏制药，今年以“引领创新，守护生命”为主题，将携创历史新高的十余款即将在华上市及未来管线产品的首展首秀登场，覆盖肿瘤、免疫、神经科学、眼科等全疾病领域，加速其向综合领航者的跨越。罗氏制G药中国总裁边欣女士表示，进博会的“加速度”已让近15款罗氏创新药从展品变为商品，切实惠及了中国患者。 此次罗氏带来的首秀产品中，佳罗华®（奥妥珠单抗）因其在狼疮性肾炎III期临床试验中取得的积极结果而备受关注。同时，全球首个、目前唯一的眼内植入物PDS（港式给药系统）也将惊艳亮相，这个仅有米粒大小的植入物可实现长达半年的持续给药，将革命性地改善眼底疾病患者的治疗体验。除了重磅产品，罗氏还将首次通过全景模型展示其最新投资20.4亿人民币新建的生物制药生产基地，这一举措标志着其在华战略已从药品引进深化至高端制造的本土化，彰显了深耕中国市场的百年承诺。 四大全球首发，以前沿科技拥抱中国生活场景 第四次亮相进博会的索尼，将以“创意无界，共启未来”为主题，全面展示其作为一家创意娱乐公司如何通过技术力量，深度融入中国社会生活的方方面面。索尼此次带来了四项重磅的“全球首发”技术与解决方案，每一项都精准地回应了中国市场的独特需求和未来趋势。 在智慧出行领域，索尼将全球首发**“语义慧行”可透视车联网预警系统**，通过创新的“透视”视觉体验提升驾驶安全；同时，“灵感之窗”随行切换的沉浸式景观体验将把智能座舱变为激发创意的移动空间。在社会民生领域，针对老龄化社会需求，索尼将展出AI跌倒监测传感设备，在保护隐私的前提下为老年人提供可靠的安全监测。而在其核心的娱乐体验上，《虫鸣幻林》触感沉浸自然空间将通过整合视、听、触、风等多重感官，为参观者构建一个前所未有的梦幻微观昆虫世界。 本土化战略成果凸显，“为中国制造”成展台主角 日化巨头花王连续第八年参展，今年的展台将呈现出鲜明的“本土化”特色，众多“为中国制造”的国产展品将从幕后走向台前，成为绝对主角。这标志着花王的中国战略已从单纯的“产品引进”全面转向“本土研发、本土生产”的深度融合阶段，以更快的速度、更精准的洞察来响应中国消费者的需求。 此次花王带来的展品均是其本土化战略的结晶。例如，珂润品牌将展出针对中国市场多发的“红荒肌”问题而研发的精华露系列新品；芙丽芳丝将展示其专为中国油性肌肤定制的“微米赤岩火山泥洁面”；美舒律则带来了专为中国“低头族”和“久坐族”设计的蒸汽舒肩暖颈贴。为了让参观者直观感受这些“中国定制”产品的技术实力，花王还将在现场设置“肌源氨基酸LAB”实验演示、UV相机防晒效果观测等一系列沉浸式互动体验。 随着第八届进博会的即将启幕，一个更加开放的中国市场正向世界张开怀抱。从前沿医药到创新科技，再到贴近日常生活的消费精品，全球企业正通过进博会这一平台，加速将全球顶尖的“展品”变为中国市场的“商品”，与中国消费者共享发展机遇，共创美好未来。

Naver Corp and Kakao Corp, two of South Korea's biggest IT companies, have shared innovative uses of AI in healthcare. In the HIMSS24 APAC panel session, " Tech Titans in Health: Naver and Kakao’s Role in Transforming Healthcare," Kakao Healthcare CEO Dr Hwang Hee and Dr Dongchul Cha, head of the Medical Innovation Centre at NAVER Healthcare Lab, shared their organisation’s respective contributions in advancing digital health in South Korea. Dr Hwang discussed potential solutions aimed at clinical data optimisation. "There are so many options to choose from, but from the perspective of the technology, I think, federated learning is a very promising and optimistic solution to address [data] hurdles." Given the unstructured nature of patient data, federated learning and training AI models for generating structured clinical data may hold key, Dr Hwang suggested. "We can use conventional [natural language processing] NLP combined with [large language models] LLM for the model training set. Kakao Healthcare developed and deployed automapping for standardising code for international [data management] standards." This process, he continued, could reduce human and economic resources by up to 70%-80%. Dr Cha shared a similar process at Naver Healthcare Lab. "[Naver] recently launched a symptom checker where users can view health symptoms and make reservations with the doctors. The patient’s medical history would be integrated with the EMR, and both parties can save time," he explained. "Records will be automatically transformed [into] clinically arranged doctors' notes. I, as a doctor, can move on to physical examination after gaining the notes, reducing my cognitive burden." Dr Cha stressed the value of additional physician and specialist input in combating potential "AI hallucinations." "We recruited a group of physicians and specialists to verify all answers [on the platform]. There are two benefits to using this approach: users get verifiable answers, and irrelevant AI questions can be replaced with valuable questions phrased by specialist clinicians." Such innovation, Dr Cha said, serves as a "doctor friend" that will always be there for the patients, all while helping virtually raise medical capacities.